AltimmuneALT
Market Cap: $441M
About: Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
Employees: 59
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
54% more call options, than puts
Call options by funds: $12.4M | Put options by funds: $8.07M
15% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 40
13% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 46
4% more funds holding
Funds holding: 166 [Q1] → 172 (+6) [Q2]
26.84% less ownership
Funds ownership: 86.61% [Q1] → 59.77% (-26.84%) [Q2]
41% less capital invested
Capital invested by funds: $474M [Q1] → $282M (-$192M) [Q2]
75% less funds holding in top 10
Funds holding in top 10: 4 [Q1] → 1 (-3) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
HC Wainwright & Co. Patrick Trucchio 30% 1-year accuracy 40 / 135 met price target | 94%upside $12 | Buy Reiterated | 22 Aug 2024 |
B. Riley Securities Mayank Mamtani 50% 1-year accuracy 13 / 26 met price target | 223%upside $20 | Buy Reiterated | 12 Aug 2024 |
B. Riley Securities Mayank Mamtani 50% 1-year accuracy 13 / 26 met price target | 223%upside $20 | Buy Reiterated | 25 Jun 2024 |
Piper Sandler Yasmeen Rahimi 54% 1-year accuracy 15 / 28 met price target | 303%upside $25 | Overweight Maintained | 21 Jun 2024 |
Financial journalist opinion
Based on 6 articles about ALT published over the past 30 days